Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. The Chinese biotech ticked the publication of multiple ascending dose data off its to-do list ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Competition ...
Structure Therapeutics Inc. develops oral small molecule medicines to replace expensive injectable biologics and peptides. Lead candidate GSBR-1290 shows modest weight loss results in clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results